• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety and Practicalities of Bispecific T-Cell Engager Administration in a District General Hospital Setting.

作者信息

Lau Benjamin, Gabrie Simran, Hobbs Prudence, Newman Joel, Elzein Abier, Sargant Nigel, Cowley Anna, Nikolova Albena, Flanagan Cliona, Burt Lorraine, Saddleton Maggie, Evans Clare, Street Theresa, Mahbak Hiba, Lazaro Arturo, Grace Richard, Jones John R

机构信息

Department of Haematology Eastbourne District General Hospital East Sussex Healthcare NHS Trust Eastbourne UK.

Brighton and Sussex Medical School Brighton UK.

出版信息

EJHaem. 2025 Jun 6;6(3):e70074. doi: 10.1002/jha2.70074. eCollection 2025 Jun.

DOI:10.1002/jha2.70074
PMID:40485904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12141921/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ac8/12141921/a23fb263df25/JHA2-6-e70074-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ac8/12141921/a23fb263df25/JHA2-6-e70074-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ac8/12141921/a23fb263df25/JHA2-6-e70074-g001.jpg

相似文献

1
Safety and Practicalities of Bispecific T-Cell Engager Administration in a District General Hospital Setting.双特异性T细胞衔接器在地区综合医院环境中的给药安全性与实用性
EJHaem. 2025 Jun 6;6(3):e70074. doi: 10.1002/jha2.70074. eCollection 2025 Jun.
2
T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.T细胞衔接抗体可使T细胞控制小鼠体内的HBV感染并靶向HBsAg阳性肝癌。
J Hepatol. 2021 Nov;75(5):1058-1071. doi: 10.1016/j.jhep.2021.06.022. Epub 2021 Jun 23.
3
Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma.分泌αCD133-αCD3 双特异性 T 细胞衔接器的 T 细胞对胆管癌的抗肿瘤活性。
PLoS One. 2022 Mar 21;17(3):e0265773. doi: 10.1371/journal.pone.0265773. eCollection 2022.
4
[The Chinese clinical expert consensus for the BCMA bispecific T cell engager in the treatment of multiple myeloma (2025)].《BCMA双特异性T细胞衔接器治疗多发性骨髓瘤中国临床专家共识（2025年版）》
Zhonghua Xue Ye Xue Za Zhi. 2025 Mar 14;46(3):209-215. doi: 10.3760/cma.j.cn121090-20250202-00050.
5
Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.双特异性自然杀伤细胞衔接器靶向 BCMA 比 T 细胞衔接器产生更强的抗肿瘤作用和更少的促炎细胞因子。
Front Immunol. 2023 Apr 11;14:1113303. doi: 10.3389/fimmu.2023.1113303. eCollection 2023.
6
Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.一种采用交叉双可变域（CODV）形式的新型CD3-CD123双特异性T细胞衔接器用于急性髓系白血病（AML）治疗的临床前开发。
Oncoimmunology. 2021 Aug 31;10(1):1945803. doi: 10.1080/2162402X.2021.1945803. eCollection 2021.
7
[Chinese consensus for the bispecific T cell engager in the treatment of acute lymphoblastic leukemia (2024)].《双特异性T细胞衔接器治疗急性淋巴细胞白血病中国专家共识（2024年版）》
Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):629-636. doi: 10.3760/cma.j.cn121090-20240528-00194.
8
Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins.激活不同的抗病毒 T 细胞免疫：双特异性和三特异性 T 细胞募集抗体与靶向 HBV 包膜蛋白的嵌合抗原受体的比较。
Front Immunol. 2022 Nov 3;13:1029214. doi: 10.3389/fimmu.2022.1029214. eCollection 2022.
9
Corrigendum: Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.勘误：与T细胞衔接器相比，靶向BCMA的双特异性NK细胞衔接器具有更强的抗肿瘤作用且产生的促炎细胞因子更少。
Front Immunol. 2024 Jan 16;15:1365027. doi: 10.3389/fimmu.2024.1365027. eCollection 2024.
10
Enhancing T cell cytotoxicity in multiple myeloma with bispecific αPD-L1 × αCD3 T cell engager-armed T cells and low-dose bortezomib therapy.使用双特异性αPD-L1×αCD3 T细胞衔接器武装的T细胞和低剂量硼替佐米疗法增强多发性骨髓瘤中的T细胞细胞毒性。
Biomed Pharmacother. 2025 Mar;184:117878. doi: 10.1016/j.biopha.2025.117878. Epub 2025 Jan 31.

本文引用的文献

1
Bispecific Antibodies in Hematological Malignancies: A Scoping Review.血液系统恶性肿瘤中的双特异性抗体：一项范围综述
Cancers (Basel). 2023 Sep 14;15(18):4550. doi: 10.3390/cancers15184550.
2
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.Elranatamab 治疗复发/难治性多发性骨髓瘤：MagnetisMM-3 期临床试验结果。
Nat Med. 2023 Sep;29(9):2259-2267. doi: 10.1038/s41591-023-02528-9. Epub 2023 Aug 15.
3
Strategies for clinical dose optimization of T cell-engaging therapies in oncology.肿瘤学中 T 细胞结合疗法的临床剂量优化策略。
MAbs. 2023 Jan-Dec;15(1):2181016. doi: 10.1080/19420862.2023.2181016.
4
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.塔奎单抗，一种用于多发性骨髓瘤的靶向 GPRC5D 的 T 细胞双特异性抗体。
N Engl J Med. 2022 Dec 15;387(24):2232-2244. doi: 10.1056/NEJMoa2204591. Epub 2022 Dec 10.
5
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.连续双特异性分子暴露诱导的 T 细胞耗竭可通过无治疗间隔得到改善。
Blood. 2022 Sep 8;140(10):1104-1118. doi: 10.1182/blood.2022015956.
6
Teclistamab in Relapsed or Refractory Multiple Myeloma.特卡昔单抗治疗复发或难治性多发性骨髓瘤。
N Engl J Med. 2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5.
7
T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?双特异性抗体在多发性骨髓瘤中的应用：一场革命？
Blood. 2022 Jun 30;139(26):3681-3687. doi: 10.1182/blood.2021014611.
8
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.双特异性 T 细胞衔接器：一种用于血液系统恶性肿瘤治疗的新兴疗法。
J Hematol Oncol. 2021 May 3;14(1):75. doi: 10.1186/s13045-021-01084-4.
9
Emerging immunotherapies in multiple myeloma.多发性骨髓瘤的新兴免疫疗法。
BMJ. 2020 Sep 21;370:m3176. doi: 10.1136/bmj.m3176.
10
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.ASTCT 细胞因子释放综合征和免疫效应细胞相关神经系统毒性的共识分级标准。
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.